General MedicationsINJECTIONStandard
OPDIVO
NIVOLUMAB
Standard Dose
100MG/10ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview OPDIVO is listed in Drugs@FDA under application 125527 (BLA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient NIVOLUMAB Form and strength INJECTABLE;INJECTION - 100MG/10ML Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2015-03-04 00:00:00.
Structured Monograph
Clinical summary
Approval overview OPDIVO is listed in Drugs@FDA under application 125527 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient NIVOLUMAB Form and strength INJECTABLE;INJECTION - 100MG/10ML Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2015-03-04 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.